JP5027804B2 - ヒト化抗ｃｄ４０抗体およびその使用方法 - Google Patents

ヒト化抗ｃｄ４０抗体およびその使用方法 Download PDF

Info

Publication number
JP5027804B2
JP5027804B2 JP2008513805A JP2008513805A JP5027804B2 JP 5027804 B2 JP5027804 B2 JP 5027804B2 JP 2008513805 A JP2008513805 A JP 2008513805A JP 2008513805 A JP2008513805 A JP 2008513805A JP 5027804 B2 JP5027804 B2 JP 5027804B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
binding
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008513805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008541733A (ja
JP2008541733A5 (enExample
Inventor
プレスタ，レオナルド，ジー．
オコンネル，ロリ，ワイ．
ドロニナ，スヴェトラナ，オー．
Original Assignee
シアトル ジェネティクス，インコーポレーテッド
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5027804(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シアトル ジェネティクス，インコーポレーテッド, ジェネンテック， インコーポレイテッド filed Critical シアトル ジェネティクス，インコーポレーテッド
Publication of JP2008541733A publication Critical patent/JP2008541733A/ja
Publication of JP2008541733A5 publication Critical patent/JP2008541733A5/ja
Application granted granted Critical
Publication of JP5027804B2 publication Critical patent/JP5027804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008513805A 2005-05-26 2006-05-26 ヒト化抗ｃｄ４０抗体およびその使用方法 Active JP5027804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68485305P 2005-05-26 2005-05-26
US60/684,853 2005-05-26
PCT/US2006/020688 WO2006128103A2 (en) 2005-05-26 2006-05-26 Humanized anti-cd40 antibodies and their methods of use

Publications (3)

Publication Number Publication Date
JP2008541733A JP2008541733A (ja) 2008-11-27
JP2008541733A5 JP2008541733A5 (enExample) 2009-07-16
JP5027804B2 true JP5027804B2 (ja) 2012-09-19

Family

ID=37452957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513805A Active JP5027804B2 (ja) 2005-05-26 2006-05-26 ヒト化抗ｃｄ４０抗体およびその使用方法

Country Status (19)

Country Link
US (4) US8303955B2 (enExample)
EP (1) EP1885399B1 (enExample)
JP (1) JP5027804B2 (enExample)
KR (1) KR100991010B1 (enExample)
CN (1) CN101237882B (enExample)
AT (1) ATE485057T1 (enExample)
AU (1) AU2006249305B2 (enExample)
BR (1) BRPI0610470A2 (enExample)
CA (1) CA2609269C (enExample)
CR (1) CR9562A (enExample)
DE (1) DE602006017690D1 (enExample)
EC (1) ECSP078026A (enExample)
ES (1) ES2354865T3 (enExample)
IL (1) IL187594A0 (enExample)
MA (1) MA29595B1 (enExample)
NO (1) NO341793B1 (enExample)
PL (1) PL1885399T3 (enExample)
RU (1) RU2407544C2 (enExample)
WO (1) WO2006128103A2 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2354865T3 (es) * 2005-05-26 2011-03-18 Seattle Genetics, Inc. Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.
WO2007075326A2 (en) * 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using cd40 binding agents
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2222875B1 (en) 2007-11-07 2014-08-20 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
AU2010222929B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
CA2754906C (en) 2009-03-10 2021-02-09 Baylor Research Institute Antigen presenting cell targeted fusion proteins comprising a linker for increased stability
PT2406286T (pt) 2009-03-10 2016-08-19 Baylor Res Inst Anticorpos anti-cd40 e seus usos
BRPI1011394A8 (pt) * 2009-04-18 2018-06-26 Genentech Inc método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40
WO2011084605A1 (en) 2009-12-16 2011-07-14 The Trustees Of The University Of Pennsylvania Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
RS57114B1 (sr) 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
WO2012135132A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
AU2012249454B2 (en) 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
SG10201707813YA (en) * 2011-10-11 2017-11-29 Medimmune Llc Cd40l-specific tn3-derived scaffolds and methods of use thereof
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9676861B2 (en) 2012-10-30 2017-06-13 Apexigen, Inc. Anti-CD40 antibodies and methods of use
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
KR102632731B1 (ko) * 2014-04-30 2024-02-01 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
CA2957146A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
CN107073118B (zh) * 2014-10-29 2022-03-01 西雅图基因公司 非岩藻糖基化抗cd40抗体的剂量和给药
US10864268B2 (en) * 2014-11-18 2020-12-15 Janssen Pharmaceutica Nv CD47 antibodies, methods, and uses
SMT202100132T1 (it) 2015-04-13 2021-05-07 Five Prime Therapeutics Inc Terapia di combinazione per il cancro
PH12018500445B1 (en) * 2015-09-01 2022-08-10 Boehringer Ingelheim Int Use of anti-cd40 antibodies for treatment of lupus nephritis
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
EP3355921A4 (en) * 2015-09-30 2019-05-22 Janssen Biotech, Inc. ANTAGONIST ANTIBODIES SPECIFICALLY BINDING TO HUMAN CD40 AND METHODS OF USE
WO2017062653A2 (en) * 2015-10-08 2017-04-13 The Board Of Trustees Of The Leland Stanford Junior University Blockade of tim-1 for treating graft-versus-host disease
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
EA039944B1 (ru) * 2016-01-27 2022-03-30 Бёрингер Ингельхайм Интернациональ Гмбх Применение антител к cd40 для лечения волчаночного нефрита
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
US10669344B2 (en) 2016-08-12 2020-06-02 Janssen Biotech, Inc. Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
US11186626B2 (en) 2016-10-11 2021-11-30 Integrated Biotherapeutics, Inc. Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
US10828375B2 (en) * 2016-11-07 2020-11-10 Seattle Genetics, Inc. Distribution of engineered-cysteine caps
WO2018088850A2 (ko) * 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
KR102364599B1 (ko) * 2017-04-04 2022-02-21 에프. 호프만-라 로슈 아게 Cd40 및 fap에 특이적으로 결합할 수 있는 새로운 이중특이적 항원 결합 분자
EP3632932A4 (en) 2017-06-01 2021-08-18 Jiangsu Hengrui Medicine Co. Ltd. ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CA3076027A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Bispecific 2+1 contorsbodies
KR102813744B1 (ko) * 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
SG11202102477QA (en) * 2018-10-01 2021-04-29 Hoffmann La Roche Bispecific antigen binding molecules comprising anti-fap clone 212
JP2022511396A (ja) * 2018-10-01 2022-01-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
KR20210097750A (ko) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
TW202039558A (zh) 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2020253722A1 (en) * 2019-06-17 2020-12-24 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
WO2021048135A1 (en) 2019-09-09 2021-03-18 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
TWI851885B (zh) 2020-03-30 2024-08-11 大陸商正大天晴藥業集團股份有限公司 結合cd40的抗體及其用途
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
TW202229348A (zh) 2020-09-30 2022-08-01 美商西健公司 使用sea-cd40治療葡萄膜黑色素瘤
JP2023548538A (ja) 2020-11-08 2023-11-17 シージェン インコーポレイテッド 併用療法
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
EP4347657A1 (en) 2021-05-25 2024-04-10 Seagen Inc. Methods of quantifying anti-cd40 antibodies
CN115403670A (zh) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US20250009877A1 (en) 2021-07-30 2025-01-09 Seagen Inc. Treatment for cancer
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
EP4507779A1 (en) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5985847A (en) * 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5597569A (en) * 1993-10-25 1997-01-28 Bristol-Myers Squibb Company Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
AU735459B2 (en) 1997-01-30 2001-07-12 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
DE69927262T2 (de) * 1998-05-23 2006-04-27 Leiden University Medical Center Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
DK1341899T3 (da) * 2000-12-14 2006-04-10 Genentech Inc Bakterieværtsstammer
ATE472338T1 (de) * 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
EP2221315A1 (en) * 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US20060003412A1 (en) * 2003-12-08 2006-01-05 Xencor, Inc. Protein engineering with analogous contact environments
JP2008515774A (ja) * 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
CN101223448B (zh) * 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
ES2354865T3 (es) * 2005-05-26 2011-03-18 Seattle Genetics, Inc. Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.

Also Published As

Publication number Publication date
US20130315900A1 (en) 2013-11-28
WO2006128103A2 (en) 2006-11-30
US20090181015A1 (en) 2009-07-16
PL1885399T3 (pl) 2011-04-29
IL187594A0 (en) 2008-03-20
JP2008541733A (ja) 2008-11-27
KR100991010B1 (ko) 2010-10-29
DE602006017690D1 (de) 2010-12-02
CR9562A (es) 2008-03-06
ECSP078026A (es) 2008-03-26
WO2006128103A3 (en) 2007-01-18
RU2407544C2 (ru) 2010-12-27
CA2609269A1 (en) 2006-11-30
RU2007148932A (ru) 2009-07-10
CN101237882B (zh) 2012-08-15
ATE485057T1 (de) 2010-11-15
US20130023047A1 (en) 2013-01-24
US8303955B2 (en) 2012-11-06
ES2354865T3 (es) 2011-03-18
CA2609269C (en) 2014-08-05
MA29595B1 (fr) 2008-07-01
AU2006249305B2 (en) 2012-10-18
AU2006249305A1 (en) 2006-11-30
EP1885399A4 (en) 2009-04-22
BRPI0610470A2 (pt) 2010-06-22
NO20076404L (no) 2008-02-13
EP1885399A2 (en) 2008-02-13
EP1885399B1 (en) 2010-10-20
CN101237882A (zh) 2008-08-06
NO341793B1 (no) 2018-01-22
KR20080030958A (ko) 2008-04-07
US8492531B2 (en) 2013-07-23
US20140193405A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
JP5027804B2 (ja) ヒト化抗ｃｄ４０抗体およびその使用方法
US20220153857A1 (en) Anti-cd40 antibodies
HK1239706B (en) Anti-cd40 antibodies
HK1239706A1 (en) Anti-cd40 antibodies
HK1178176A (zh) 抗-cd40抗体
HK1178176B (en) Anti-cd40 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120123

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120529

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120622

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150629

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5027804

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250